Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-11-17
2000-07-11
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514397, A61K 3156
Patent
active
060873612
ABSTRACT:
Methods are disclosed for treating a mammal with a condition that responds to .alpha.2 agonist treatment without causing cardiovascular side effects using compounds of the formula ##STR1## wherein R.sub.1 is H, alkyl or 1 to 4 carbon atoms or a halogen atom, X is O or NH and A is H or an oxo group and wherein said compound does not cause a concomitant reduction in blood pressure of said mammal.
REFERENCES:
patent: 3459763 (1969-08-01), Gruenfeld
patent: 5077292 (1991-12-01), Gluchowski
patent: 5091528 (1992-02-01), Gluchowski
patent: 5112822 (1992-05-01), Gluchowski
patent: 5663189 (1997-09-01), Maurer et al.
Ernsberger et al, "A Second Generation of Centrally Acting Antihypertensive Agents Act on Putative I.sub.1 -Imidazoline Receptors", Journal of Cardiovascular Pharmacology 20 (Suppl. 4), S1-S10 1992.
U. S. Application No. 08/086,482, Maurer et al., filed on Jul. 1, 1993.
Bousquet et al, "Imidazoline Receptors A New Concept in Central Regulation of the Arterial Blood Pressure", American Journal of Hypertension, Inc., 1992:5:47S-50S.
Physical Organic Chemistry, N.S. Isaacs Universities Press (Belfast) Ltd., 1987 pp. 62-67.
Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, R.F. Doerge (ed.) J.B. Lipincott Co. 1982, pp. 41-43.
Jen et al, "Amines and Related Compounds. 6.sup.1 Studies on Structure-Activity Relationships of Antihypertensive and Antisecretory Agents Related to Clonidine", J. Med. Chem., 18(1), 90-99(1975).
Ruffolo RR, Jr. (ed): .alpha.-Adrenoceptors: Molecular Biology, Biochemistry and Pharmacology, Prog. Basic Clin Pharmacol, Basel, Karger, 1991, vol. 8, pp. 75-114.
M.C. Michel and P. Ernsberger in TiPS, 13, pp. 369-379 (Oct. 1992).
Haxhiu, M.A., et al, J. Cardiovasc. Pharmacol. 24(suppl. 1) pp. S1-S8 (1994).
Harron, D.W. [Am. J. Hypertens., 5(4,Pt.2) pp. 91S-98S9Apr. 1992).
Codd, E.E., et al. Life Sci., 56(2) p. 63-74(Dec. 2, 1994).
Ernsberger, P., et al, Cardivasc. Drugs Ther., 8(Suppl. 1) pp. 27-41(Mar. 1994).
Jin, Y. et al, J. Ocul. Pharmacol., 10(1) pp. 359-369(1994).
Millan, M., J. Eur. J. Pharmacol., 215(2-3)pp. 355-356(1992).
CA 114:63020, Anderman, 1990.
CA 95:12796, Newsome et al, 1981.
CA 118:66873, Sims et al, 1992.
Burke James A.
Lai Ronald K.
Munk Stephen A.
Allergan Sales Inc.
MacMillan Keith D.
LandOfFree
Aryl-imidazolines and aryl-imidazoles useful as .alpha.-2 adrene does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl-imidazolines and aryl-imidazoles useful as .alpha.-2 adrene, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl-imidazolines and aryl-imidazoles useful as .alpha.-2 adrene will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-542665